Alexion’s Ultomiris Wins English Funding, Janssen’s Erleada Rejected
NICE Guidance Due On Astellas’s Xtandi For Prostate Cancer
Executive Summary
Recommendations this week from health technology assessment body NICE relate to the treatment of two rare blood disorders with Ultomiris, and treating prostate cancer with Erleada.
You may also be interested in...
NICE Reverses English Funding Rejection For Erleada After Janssen Drops Price
The androgen receptor inhibitor Erleada is now considered to be a cost-effective use of National Health Service resources.
Astellas Pips Janssen To Post With English Funding For New Prostate Cancer Indication
NICE’s decision today affirming the cost effectiveness of Astellas Pharma’s Xtandi for hormone-sensitive metastatic prostate cancer contrasts with the health technology assessment body’s guidance last month for Janssen’s Erleada.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.